Ovid Therapeutics announced it has significantly expanded its SAB with the appointment of renowned neurologists, neuroscientists, and epileptologists. The new SAB members were appointed to advise Ovid on the potential application of its unique pipeline programs and mechanisms of action to broader areas of neurology in which they may offer therapeutic promise. The SAB is chaired by Professor Robert Langer, who convened the first meeting of the expanded SAB at Massachusetts Institute of Technology in July 2024. Members of the Ovid Therapeutics Scientific Advisory Board: Robert Langer; Imad Najim; Raman Sankar; Jamie Maguire; Jeffrey Noebels.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID:
- Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
- Ovid Therapeutics announces eNeuro published studies on OV329 mechanism
- eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
- Ovid Therapeutics, Graviton announce data from trial of OV888/GV101 capsule
- Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations